438. An Observational Study Evaluating the Seroprotection of HepB-alum Vaccine and HepB-CpG Vaccine in Adults Living with HIV

Abstract Background Hepatitis B virus (HBV) vaccine seroprotection rates with conventional aluminum adjuvanted recombinant HBV vaccines (HepB-alum) among people HIV (PWH) are varied. HepB-CpG, a novel vaccine, has shown higher in immunocompetent patients but is not well studied PWH. There no published studies comparing between HepB-alum and HepB-CpG The purpose of this study was to evaluate compare the incidence versus adults at least 18 years age HIV. Methods This retrospective, observational, cohort screened for inclusion diagnosed who received 3-dose series or 2-dose January 1, 2015 through December 31, 2021 community health center Phoenix, Arizona. Patients had confirmed diagnosis hepatitis surface antibody < 10 IU/L time first dose were included until an adequate sample size achieved. primary outcome seroconversion Secondary outcomes identifying factors associated increased likelihood response vaccination. Seroconversion data analyzed using Fisher’s exact test BlueSky Statistics. Results A total 121 study, 59 61 cohort. In cohort, 57.6% (34/59) achieved seroconversion, compared 93.4% (57/61) group (p 0.001). Univariate comparisons comorbidities cohorts found significant differences sex, body mass index, diabetic status, kidney/liver disease, CD4 count, viral load, active/prior history substance use. Conclusion Among PWH single center, provided statistically against HepB-alum. rate due demographics reported comorbidities. Disclosures Carlos Hartmann, MD, Viiv Pharmaceuticals: Speaker.